HK1221908A1 - 多特異 試劑，其製備方法和用途 - Google Patents

多特異 試劑，其製備方法和用途

Info

Publication number
HK1221908A1
HK1221908A1 HK16110125.9A HK16110125A HK1221908A1 HK 1221908 A1 HK1221908 A1 HK 1221908A1 HK 16110125 A HK16110125 A HK 16110125A HK 1221908 A1 HK1221908 A1 HK 1221908A1
Authority
HK
Hong Kong
Prior art keywords
polyspecificity
preparation
methods
reagents
polyspecificity reagents
Prior art date
Application number
HK16110125.9A
Other languages
English (en)
Inventor
Piotr Bobrowicz
Amber D Hanna
Jerry M Thomas
Original Assignee
Adimab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adimab Llc filed Critical Adimab Llc
Publication of HK1221908A1 publication Critical patent/HK1221908A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Ecology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HK16110125.9A 2013-04-29 2016-08-25 多特異 試劑，其製備方法和用途 HK1221908A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361817072P 2013-04-29 2013-04-29
PCT/US2014/035958 WO2014179363A1 (en) 2013-04-29 2014-04-29 Polyspecificity reagents, methods for their preparation and use

Publications (1)

Publication Number Publication Date
HK1221908A1 true HK1221908A1 (zh) 2017-06-16

Family

ID=51789710

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16110125.9A HK1221908A1 (zh) 2013-04-29 2016-08-25 多特異 試劑，其製備方法和用途

Country Status (4)

Country Link
US (4) US20140323315A1 (zh)
EP (1) EP2991679A4 (zh)
HK (1) HK1221908A1 (zh)
WO (1) WO2014179363A1 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA030792B1 (ru) 2009-11-30 2018-09-28 Янссен Байотек, Инк МУТИРОВАННЫЕ Fc АНТИТЕЛ С УСТРАНЕННЫМИ ЭФФЕКТОРНЫМИ ФУНКЦИЯМИ
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
US20140323315A1 (en) 2013-04-29 2014-10-30 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
US11564991B2 (en) 2014-11-12 2023-01-31 University Of Mississippi Medical Center Molecular-size of elastin-like polypeptide delivery system for therapeutics modulates intrarenal deposition and bioavailability
US10322189B2 (en) 2014-11-12 2019-06-18 University Of Mississippi Medical Center Kidney-targeted drug delivery systems
EP3878861A1 (en) * 2015-02-16 2021-09-15 Lonza Ltd. Cl and/or ch1 mutated antibodies for drug conjugation
IL254887B2 (en) 2015-04-07 2023-11-01 Alector Llc Anti-sortilin antibodies and methods of using them
PT3356413T (pt) 2015-10-01 2022-04-04 Potenza Therapeutics Inc Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas
CN109153713B (zh) 2016-03-10 2022-12-27 艾科赛扬制药股份有限公司 活化素2型受体结合蛋白及其用途
IL303833A (en) 2016-10-21 2023-08-01 Adimab Llc Respiratory syncytial virus antibodies and methods for their production and use
JP7265984B2 (ja) 2016-10-21 2023-04-27 アディマブ， エルエルシー 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
WO2018075974A2 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
AU2018219887B2 (en) 2017-02-08 2024-08-15 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201907271PA (en) * 2017-02-10 2019-09-27 Dragonfly Therapeutics Inc Proteins binding psma, nkg2d and cd16
AU2018219348A1 (en) * 2017-02-10 2019-08-29 Dragonfly Therapeutics, Inc. Proteins binding BCMA, NKG2D and CD16
CA3235295A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
EP3585424A4 (en) * 2017-02-27 2021-01-13 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS TARGETED BY CAIX, ANO1, MESOTHELIN, TROP2, CEA OR CLAUDIN-18.2
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
WO2019023504A1 (en) 2017-07-27 2019-01-31 Iteos Therapeutics Sa ANTI-TIGIT ANTIBODIES
AU2018306463A1 (en) 2017-07-27 2020-03-05 iTeos Belgium SA Anti-TIGIT antibodies
EP3735271A4 (en) 2018-01-04 2022-06-15 Iconic Therapeutics, Inc. ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
MX2020012286A (es) 2018-05-16 2021-04-28 Janssen Biotech Inc Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t.
CN112384532A (zh) 2018-06-29 2021-02-19 艾利妥 抗SIRP-β1抗体及其使用方法
US11396546B2 (en) 2018-07-13 2022-07-26 Alector Llc Anti-Sortilin antibodies and methods of use thereof
CN115057932A (zh) 2018-09-27 2022-09-16 提泽纳治疗公司 抗hla-g抗体、包含抗hla-g抗体的组合物和使用抗hla-g抗体的方法
SG11202107474RA (en) 2019-01-07 2021-08-30 iTeos Belgium SA Anti-tigit antibodies
US11248038B2 (en) 2019-03-29 2022-02-15 University Of Mississippi Medical Center Molecular-size of elastin-like polypeptide delivery system for therapeutics modulates intrarenal deposition and bioavailability

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US7129326B2 (en) 2000-04-14 2006-10-31 Genencor International, Inc. Methods for selective targeting
DE60141088D1 (de) 2000-04-14 2010-03-04 Genencor Int Verfahren zur selektiven zielen
US20040038307A1 (en) 2002-05-10 2004-02-26 Engeneos, Inc. Unique recognition sequences and methods of use thereof in protein analysis
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
WO2005073375A1 (en) * 2004-01-30 2005-08-11 Maxygen Holdings Ltd. Regulated stop codon readthrough
FR2895263B1 (fr) * 2005-12-26 2008-05-30 Lab Francais Du Fractionnement Concentre d'immunoglobines g (lg) appauvri en anticorps anti-a et anti-b, et en igg polyreactives
CA2677383A1 (en) 2007-02-09 2008-08-21 Medimmune, Llc Antibody library display by yeast cell plasma membrane
GB0725153D0 (en) * 2007-12-21 2008-01-30 Medinnova As Protein analysis
WO2010059981A2 (en) * 2008-11-21 2010-05-27 Dgen Biotech Limited High complexity mammalian display library and methods of screening
MY160472A (en) 2009-07-17 2017-03-15 Bioatla Llc Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
JP2013524847A (ja) * 2010-05-05 2013-06-20 アリックス インコーポレイテッド 抗体でヒト赤血球を官能化する方法
FR2977893B1 (fr) * 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
US20140323315A1 (en) 2013-04-29 2014-10-30 Adimab, Llc Polyspecificity reagents, methods for their preparation and use

Also Published As

Publication number Publication date
US20160077105A1 (en) 2016-03-17
EP2991679A4 (en) 2016-12-07
WO2014179363A1 (en) 2014-11-06
US20210156872A1 (en) 2021-05-27
EP2991679A1 (en) 2016-03-09
US20190079098A1 (en) 2019-03-14
US10883997B2 (en) 2021-01-05
US20140323315A1 (en) 2014-10-30
US10156574B2 (en) 2018-12-18

Similar Documents

Publication Publication Date Title
HK1221908A1 (zh) 多特異 試劑，其製備方法和用途
HK1212444A1 (zh) 化驗裝置、方法和試劑
IL245935A0 (en) Methods for RNA analysis
EP2968304A4 (en) 4-PHENYLPIPERIDINES, PREPARATION THEREOF AND USE THEREOF
GB2516513B (en) Multiple Viewshed analysis
EP2968303A4 (en) OCTAHYDROCYCLOPENTAPYROLE AND THEIR PREPARATION AND USE
HK1219535A1 (zh) 用於樣品製備的裝置、系統和方法
EP2994042C0 (en) DEVICES, SYSTEMS AND METHODS FOR MEASURING BLOOD LOSS
GB2527441B (en) Analysis system
GB201319878D0 (en) Method, Array and use thereof
GB201300650D0 (en) Analysis system
HK1200230A1 (zh) 隊列分析
HK1218120A1 (zh) 三環苯並氧雜硼化合物、其製備方法與應用
HK1217990A1 (zh) 用於樣品分析的方法、裝置和系統
IL242795B (en) Preparations, methods and devices for dialysis
EP2813495A4 (en) 2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE THEREOF
EP3065712A4 (en) Microparticles, methods for their preparation and use
HK1221162A1 (zh) 提取物和含有該提取物的製劑
EP2950646A4 (en) AGROCHEMICAL COMPOSITION, PROCESS FOR PREPARATION AND USE THEREOF
HK1224011A1 (zh) 用於獲得臨床樣品的方法和系統
ZA201600015B (en) Anti-fibrogenic compounds, methods and uses thereof
EP2980096A4 (en) 2,3,5-trihydroxy-androst-6-one, as well as method of preparation and use thereof
GB201314962D0 (en) Pivot analysis method using condition group
HK1204001A1 (zh) 種 片段及其製備方法和用途
GB201319530D0 (en) DNA sample preparation